3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
4
Breast
4
Tumor-Agnostic
3
Other hematologic neoplasm
3
Sarcoma
2
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Lung Cancer - Malignant Pleural Mesothelioma
1
Interventions
Cisplatin
81
Gemcitabine
58
Carboplatin
57
Irinotecan
56
Paclitaxel
53
Pemetrexed
47
Docetaxel
39
Nivolumab
33
Fluorouracil
30
Bevacizumab
27
pembrolizumab
25
Cyclophosphamide
24
Capecitabine
24
Oxaliplatin
22
Leucovorin
21
Topotecan
19
durvalumab
17
Erlotinib Hydrochloride
17
Sorafenib
16
Everolimus
16
Etoposide
16
Bortezomib
16
Ipilimumab
15
Injections
15
Sunitinib
14
Filgrastim
14
Early Intervention, Educational
14
atezolizumab
13
alvocidib
13
Sirolimus
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
STA 9090
×
Other solid neoplasm
×
Clear all
NCT01590160
2019-11-13
MESO-02
University College, London
Phase 1/2
Completed
27 enrolled